Skip to main content
. Author manuscript; available in PMC: 2015 May 12.
Published in final edited form as: Cancer. 2010 Oct 13;117(5):897–906. doi: 10.1002/cncr.25656

Table 1.

Response and Survival Rates for Patients Receiving Second-Line Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia

24-Month Response Rate, %
Response to Agent Chronic Phase Accelerated Phase
Dasatinib, 70 mg twice daily n=387 (Mauro 200842) n=174 (Rea 200844)
 CHRa 91 50
 MCyR 62 40
 CCyR 53 33
 PFSb 80 46
 OS 94 72
Nilotinib n=321 (Kantarjian 200956,57) n=137 (Hochhaus 200958)
 CHRc 94 31
 MCyR 59 32
 CCyR 44 20
 PFS 64 NR
 OS 88 67
High-dose imatinib, 400 mg twice daily n=49 (Kantarjian 200931) –
 CHR 82 NA
 MCyR 33 NA
 CCyR 18 NA

CHR indicates complete hematologic response; MCyR, major cytogenetic response; CCyR, complete cytogenetic response; PFS, progression-free survival; OS, overall survival; NR, not reported; NA, not applicable.

a

Including patients who had a CHR at baseline.

b

Including loss of hematologic or cytogenetic response, increasing white blood count, increase in Philadelphia chromosome-positive metaphases, transition to advanced phases of CML, or death.

c

Excluding patients who had CHR at baseline.